, June 8 -- weekly diabetes medication, retatrutide, has demonstrated significant improvements in blood sugar control and weight loss among adults with type 2 diabetes, according to a Phase 3 clinical trial published in The Lancet.

The study involved 930 adults with type 2 diabetes who received either varying doses of retatrutide or a placebo over a 40-week period. Researchers found that the drug substantially lowered long-term blood glucose levels while also producing considerable weight loss.

Participants treated with retatrutide lost an average of 11.5% to 15.3% of their body weight, compared with only 2.6% among those who received the placebo. These results suggest the drug could become a promising new option alongside current treat...